2022

2022

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

Heerspink H.J.L.;Stack A.G.;Terkeltaub R.;Greene T.A.;Inker L.A.;Bjursell M.;Perl S.;Rikte T.;Erlandsson F.;Perkovic V. (2022) Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia. Nephrology Dialysis Transplantation :1461-1471

2022

Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON

Doherty J.;Morain N.O.;Stack R.;Girod P.;Tosetto M.;Inzitiari R.;Sheridan J.;Cullen G.;McDermott E.;Buckley M.;Horgan G.;Mulcahy H.;Ryan E.J.;Daghfal D.;Doran P.;Morain C.O.;Doherty G.A. (2022) Reduced Serological Response to COVID-19 Vaccines in Patients with IBD is Further Diminished by TNF Inhibitor Therapy; Early Results of the VARIATION study [VAriability in Response in IBD Against SARS-COV-2 ImmunisatiON. Journal Of Crohns &Amp; Colitis :1354-1362